Gaucher Disease


Article Author:
William Stone


Article Editor:
Samip Master


Editors In Chief:
Eric Flake


Managing Editors:
Carrie Smith
Abdul Waheed
Frank Smeeks
Kristina Soman-Faulkner
Scott Dulebohn
Sobhan Daneshfar
William Gossman
Pritesh Sheth
John Shell
Matthew Varacallo
Ahmad Malik
Mark Pellegrini
James Hughes
Beata Beatty
Richard Ciresi
Hajira Basit
Phillip Hynes


Updated:
3/23/2019 1:01:20 AM

Introduction

Gaucher disease (pronounced as GO-SHEY) is an autosomal recessive inborn error of metabolism caused by mutations in the glucocerebrosidase (GBA1) gene [1]. GBA1 is an enzyme that cleaves beta-glucosidic linkage of glucocerebroside lipids. Inborn errors of metabolism are particularly relevant in pediatrics since their presentation is very often (but not always) in the neonatal period of infancy. There are five known types of Gaucher disease: type 1, type 2, type 3, perinatal lethal and cardiovascular. The perinatal lethal form is the most severe and its complications can begin before birth or in early infancy.

Knowing the major manifestations of any inborn error of metabolism is the key to making a diagnosis. Inborn errors of metabolism primarily result from the lack (or insufficient levels) of specific enzymes needed: (1) convert fat or carbohydrates to energy or to; (2) breakdown amino acids or other metabolites, allowing them to accumulate and become toxic if not treated. Gaucher disease is a “toxic accumulation” inborn error of metabolism due to the accumulation of glucocerebroside lipids. It is the most common cause of lysosomal storage diseases. Lysosomes are subcellular organelles responsible for the physiological turnover of cell constituents. Toxic accumulation inborn errors of metabolism fall into three major categories, localized toxicity, circulating toxicity or a combination of both. Gaucher disease is an example of localized toxicity.

Etiology

The underlying cause of all forms of Gaucher disease is mutations in the GBA1 gene resulting in a lysosomal deficiency of glucocerebrosidase activity. All forms of Gaucher disease lead to the toxic accumulation of glucocerebroside lipids, primarily in the liver, spleen, and bone marrow. A glucocerebroside is composed of a glucose molecule linked to the oxygen atom on carbon atom 1 of the sphingosine moiety of ceramide. All forms of Gaucher disease are also classified as lysosomal storage disorders. There are at least 40 other lysosomal storage disorders including mucopolysaccharidosis, Tay-Sachs disease, and Fabry disease [2]. All lysosomal storage disorders tend to get worse over time, in other words, they are progressive. Lysosomes are spherical intracellular organelles where many lipids and macromolecules are delivered for degradation by hydrolytic enzymes. Lysosomes are abundant in macrophages. The lysosomes in the macrophages of patients with Gaucher disease become progressively enlarged and filled with undigested glucocerebroside. The lysosomes can eventually be filled with undigested lipids that resemble “crumpled tissue paper” when visualized by electron microscopy. In the absence of appropriate treatment, the liver can expand two-fold to three-fold its normal size and the spleen by 15-fold.

Despite knowing the precise genetic causes of most forms of Gaucher disease, the exact cause remains unknown. It is possible for patients with the same mutation to have very different signs and symptoms. It is also possible for patients with similar signs and symptoms to have very different genetic mutations. Environmental factors, as well as an individual's particular genetic makeup, most likely influence the phenotypic expression of Gaucher disease.

Epidemiology

Gaucher disease is the most common autosomal recessive disease in the Ashkenazi (Eastern European) Jewish population with a carrier frequency of 6% compared to 0.7% to 0.8% of the non-Jewish population. Cystic fibrosis (4% carrier frequency) and Tay-Sachs Disease (3.7% carrier frequency) are also common in the Ashkenazi population.

The most common form of Gaucher disease is type 1 which has a very variable phenotype ranging from early childhood symptoms to no symptoms throughout life but typically does not have a neurological component. In contrast to type 1, both type 2 and 3 are rare and do affect the central nervous system. Both type 2 and the perinatal lethal typically result in neonatal death whereas type 3 results in mid to early adulthood death.

Pathophysiology

The signs and symptoms of Gaucher disease can be classified into visceral, hematologic, skeletal, and metabolic components. The visceral components include enlarged liver and spleen (hepatosplenomegaly).

Hematological components can include thrombocytopenia, anemia, and leukopenia. Cerebroside accumulation in the bone marrow is thought to decrease platelet production resulting in low platelet count. Similarly, cerebroside accumulation in the spleen is thought to result in an excessive break down of red blood cells resulting in anemia as well as more active removal of white blood cells (WBC) resulting in a low WBC count.

The skeletal components can include bone crisis, the death of bone cells (called avascular necrosis or osteonecrosis), a low bone density compared to normal peak density, pathological bone fracture, and Erlenmeyer flask deformity. Much of these skeletal abnormalities are attributed to the buildup of glucocerebroside-laden macrophages in the bone-marrow where they restrict blood flow and the delivery nutrients and oxygen which can result in intense pain, bone cell necrosis, low bone density, and growth abnormalities.

Histopathology

Classic glycolipid-laden macrophages are found in liver biopsy and bone marrow samples.

Liver biopsy samples typically reveal glycolipid-laden Gaucher cells evident in the sinusoids, but the hepatocytes do not manifest overt glycolipid storage because of biliary excretion of glucocerebroside and because exogenous glycolipid turnover is typically handled by the mononuclear phagocytes. As hepatocytes are spared, there is a very low incidence of liver failure in individuals with Gaucher disease.

The pathologic hallmark of Gaucher disease is Gaucher cells in the macrophage-monocyte system typically found in the bone marrow. These cells have a characteristic wrinkled-paper appearance, resulting from intracytoplasmic substrate deposition, and stain positive with periodic acid–Schiff. Histologic evaluation should not be used as a primary diagnostic tool.

History and Physical

The diagnosis of Gaucher disease depends upon finding a low GBA1 enzyme level in peripheral blood leukocytes as well as establishing the presence of mutant alleles in the GBA1 gene. Despite the fact that only a blood sample is needed to diagnosis Gaucher disease, some patients undergo unnecessary invasive bone marrow or liver biopsy before making a correct diagnosis. Physician awareness of the signs and symptoms of Gaucher disease can help avoid such mishaps. Moreover, before an accurate diagnosis is made, many patients with an enlarged liver or spleen are told they could have cancer.

Evaluation

Laboratory Studies

CBC Count

  • CBC and platelet count will access the degree of cytopenia.

Liver Function Enzyme Testing

  • Mild elevation of liver enzyme levels is common; the presence of jaundice or abnormal hepatocellular synthetic function merits further study.

Coagulation

  • Regular monitoring should be performed.

Enzyme Activity

  • Diagnosis is confirmed through measurement of glucocerebrosidase activity in peripheral blood leukocytes. Less than 15% of mean normal activity is diagnostic.

Genotype Testing

  • Molecular diagnosis is often helpful in Ashkenazi patients, in whom 6 GBA1 mutations (c.84insG, L444P, N370S,  IVS2+1g>a, V394L, and R496H) account for most disease alleles.
  • In some ethnicities, sequencing of the exons of GBA1 may be necessary in order to establish the genotype.
  • Mutation analysis has limited predictive value with respect to Gaucher disease progression. Avoid relying on PCR-based tests for individual mutations because they do not reveal the presence of recombinant alleles associated with greater severity of the disease.

Associated Marker Testing

  • Angiotensin-converting enzyme, total acid phosphatase, and ferritin levels are usually elevated. These levels may normalize with treatment.
  • Monitoring chitotriosidase enzyme is useful except in the 10% of the population that has a deficiency in this protein.
  • Monitoring glucosylsphingosine levels may be useful, as the level has been shown to correlate with response to therapy.
 

Imaging

  • Ultrasonography - may reveal abdominal organomegaly.
  • MRI - may be useful in revealing early skeletal involvement (avascular necrosis, spinal degradation, and degree of bone marrow infiltration.
  • Radiography - may reveal skeletal manifestations and pulmonary involvement.
  • Dual-energy x-ray absorptiometry - may evaluate osteopenia and bone crises.
  • Echocardiograms are helpful in evaluating the possibility of pulmonary hypertension.
  • In neuronopathic Gaucher disease, monitoring of EEG, brainstem-evoked potential, swallowing studies, and neuro-ophthalmologic evaluation should be done at regular intervals.

Bone Marrow Aspiration

  • In the past, the diagnosis was made by finding classic glycolipid-laden macrophages in bone marrow aspirate. Today, aspiration is not typically needed due to alternative less invasive tests.
  • Bone marrow aspiration is not the initial diagnostic test because the blood enzyme test is more sensitive, specific, less invasive.

Liver Biopsy

  • Liver biopsy may be performed to evaluate unexplained hepatomegaly. However, a biopsy is rarely needed because a specific diagnostic test is available.
 

Treatment / Management

Treatment for Gaucher disease falls into two categories, enzyme replacement therapy and substrate reduction therapy [3].  In general, enzyme replacement therapy provides an intravenous infusion containing the enzyme that is deficient or absent in the body. In the case of Gaucher disease, this would be the GBA1 enzyme (also called beta-glucosylceramidase or beta-glucocerebrosidase). The FDA has approved both Cerezyme (imiglucerase) and VPRIV (velaglucerase alfa) for Gaucher disease type 1 and 3 enzyme replacement therapy. Enzyme replacement therapy typically cannot replace an enzyme deficient in the brain due to the blood-brain barrier and therefore is not effective for the treating the central nervous systems problems associated with type 2 and 3 Gaucher disease. Enzyme replacement therapy will help with the “non-brain” signs and symptoms associated with type 3 Gaucher disease, e.g., enlarged organs and skeletal issues.

Enzyme replacement therapy does not correct the underlying genetic defect and acts only to relieve signs, symptoms and ongoing damage caused by the accumulation of toxins. Moreover, it is possible to develop antibodies to the replacement enzyme.

Substrate reduction therapy is an orally administered small-molecule drug (not protein) that relies on a strategy distinct from that of enzyme replacement therapy. In substrate reduction therapy the goal is to reduce the levels of a substrate such that toxic accumulation of the substrate’s subsequent degradative product is diminished to a level that is clinically less toxic. In the case of Gaucher disease, the goal is to use substrate reduction therapies that can inhibit the first committed step in glycosphingolipid biosynthesis. There are two FDA-approved substrate reduction therapy drugs to treat patients with Gaucher disease, i.e., Cerdelga (eliglustat) and Zavesca (miglustat). Cerdelga, a glucosylceramide synthase inhibitor, does not effectively cross the blood-brain barrier is indicated only for type 1 Gaucher disease [4]. It is not yet known if Cerdelga is safe or effective in children. Miglustat can cross the blood-brain barrier and could, therefore, be potentially beneficial for type 2 and 3 Gaucher disease. Nevertheless, miglustat is currently indicated only for the treatment mild to moderate type 1 Gaucher disease only in adults.

Enhancing Healthcare Team Outcomes

Evaluation and treatment of Gaucher disease is difficult and requires a coordinated team approach of physicians, nurse practitioners, and physician assistants to maintain the health of the patient. [Level V]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE courses, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Gaucher Disease - Questions

Take a quiz of the questions on this article.

Take Quiz
What is the most common lysosomal storage disease?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What disorder is characterized by the absence of the enzyme glucocerebrosidase?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A patient presents with anemia, thrombocytopenia, and splenomegaly. He has been prone to numerous infections in the past. Blood work reveals an absence of the enzyme glucocerebrosidase. What is the patient's most likely diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following statements about Gaucher disease is FALSE?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Bone marrow aspirate from a certain patient revealed large multinucleated macrophage-like cells that are engorged with cytoplasmic fibrils. Which of the following is the most likely deficient enzyme in the patient?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following drugs is approved for use in Gaucher disease?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following enzymes is most likely defective Gaucher disease?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A Jewish couple of Eastern European heritage would be at increased risk of being carriers for which two diseases?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 8-year old has hepatosplenomegaly. A liver biopsy from the child show's macrophages with a crinkled appearance. Which enzyme is deficient?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following seizure disorders with cognitive impairment has reduced beta glucosylceramidase activity?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 9 month of female has problems swallowing, spasticity, and head retraction. She is diagnosed with deficiency of glucocerebrosidase. Which of the following accumulates abnormally?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What type of inheritance pattern is followed by Gaucher disease?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following defects is characteristic of Gaucher disease?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 13-year-old girl is brought in after a dizzy spell. CBC shows WBC of 5000/microliter, hematocrit of 24 percent, and platelets of 96,000/microliter. She has splenomegaly and femur x-ray shows expansion of the bone marrow in the shape of an Erlenmeyer flask. What test would provide the diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Your colleague, a pathologist, calls you after a patient underwent liver biopsy for ongoing elevated liver enzymes. The pathologist tells you that the biopsy contains some strange cells that look like "wrinkled tissue paper." What is the likely diagnosis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following inborn disorders of metabolism is associated with bony sclerosis, multiple areas of subchondral radiolucent lines (crescent sign), and flattening of bone on plain x-rays?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
You are seeing a three-year-old for the first time. The patient shows hepatosplenomegaly and fatigue secondary to anemia. Both parents are of Ashkenazi Jewish descent. What would be a reasonable evaluation?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Gaucher Disease - References

References

Stirnemann J,Belmatoug N,Camou F,Serratrice C,Froissart R,Caillaud C,Levade T,Astudillo L,Serratrice J,Brassier A,Rose C,Billette de Villemeur T,Berger MG, A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. International journal of molecular sciences. 2017 Feb 17;     [PubMed]
Ferreira CR,Gahl WA, Lysosomal storage diseases. Translational science of rare diseases. 2017 May 25;     [PubMed]
Mistry PK,Lopez G,Schiffmann R,Barton NW,Weinreb NJ,Sidransky E, Gaucher disease: Progress and ongoing challenges. Molecular genetics and metabolism. 2017 Jan - Feb;     [PubMed]
Mistry PK,Lukina E,Ben Turkia H,Shankar SP,Baris H,Ghosn M,Mehta A,Packman S,Pastores G,Petakov M,Assouline S,Balwani M,Danda S,Hadjiev E,Ortega A,Gaemers SJM,Tayag R,Peterschmitt MJ, Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial. American journal of hematology. 2017 Nov;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Pediatric-Developmental. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Pediatric-Developmental, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Pediatric-Developmental, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Pediatric-Developmental. When it is time for the Pediatric-Developmental board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Pediatric-Developmental.